Human Bcl-2 antisense therapy for lymphomas

Biochim Biophys Acta. 1999 Dec 10;1489(1):97-106. doi: 10.1016/s0167-4781(99)00139-6.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity
  • Clinical Trials, Phase I as Topic
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / genetics
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / genetics
  • Mice
  • Mice, SCID
  • Oligonucleotides, Antisense / adverse effects
  • Oligonucleotides, Antisense / therapeutic use*
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Remission Induction
  • Thionucleotides / adverse effects
  • Thionucleotides / therapeutic use*
  • Thionucleotides / toxicity
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Oligonucleotides, Antisense
  • Proto-Oncogene Proteins c-bcl-2
  • Thionucleotides
  • oblimersen